Education
About Us
Working with TipRanks
Follow Us
Kringle Pharma, Inc. (JP:4884)
:4884
4884 Stock Chart & Stats
¥452.00
-¥48.00(-4.72%)
At close: 4:00 PM EST
¥452.00
-¥48.00(-4.72%)
Day’s Range― - ―
52-Week Range¥438.00 - ¥1,322.00
Previous CloseN/A
Volume217.60K
Average Volume (3M)72.35K
Market Cap
¥3.17B
Enterprise Value¥4.30B
Total Cash (Recent Filing)¥1.63B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 12, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-33.20
Shares Outstanding7,018,200
10 Day Avg. Volume108,970
30 Day Avg. Volume72,353
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.57
Price to Sales (P/S)67.72
P/FCF Ratio-8.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Kringle Pharma, Inc. News
4884 FAQ
What was Kringle Pharma, Inc.’s price range in the past 12 months?
Kringle Pharma, Inc. lowest stock price was ¥438.00 and its highest was ¥1322.00 in the past 12 months.
What is Kringle Pharma, Inc.’s market cap?
Kringle Pharma, Inc.’s market cap is ¥3.17B.
When is Kringle Pharma, Inc.’s upcoming earnings report date?
Kringle Pharma, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 25 days.
How were Kringle Pharma, Inc.’s earnings last quarter?
Kringle Pharma, Inc. released its earnings results on Aug 08, 2025. The company reported -¥33.2 earnings per share for the quarter, missing the consensus estimate of N/A by -¥33.2.
Is Kringle Pharma, Inc. overvalued?
According to Wall Street analysts Kringle Pharma, Inc.’s price is currently Overvalued.
Does Kringle Pharma, Inc. pay dividends?
Kringle Pharma, Inc. does not currently pay dividends.
What is Kringle Pharma, Inc.’s EPS estimate?
Kringle Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kringle Pharma, Inc. have?
Kringle Pharma, Inc. has 7,018,200 shares outstanding.
What happened to Kringle Pharma, Inc.’s price movement after its last earnings report?
Kringle Pharma, Inc. reported an EPS of -¥33.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.988%.
Which hedge fund is a major shareholder of Kringle Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4884
Company Description
Kringle Pharma, Inc.
Kringle Pharma, Inc. (4884) is a biotechnology company based in Japan, focused on the research, development, and commercialization of therapeutic agents. The company specializes in regenerative medicine and is primarily engaged in the development of recombinant human HGF (Hepatocyte Growth Factor) protein for the treatment of various diseases, including acute spinal cord injury and other neurological disorders.
Technical Analysis
OncoTherapy Science
―
Cytori Cell Research Institute, Inc.
―
Oncolys BioPharma, Inc.
―
BrightPath Biotherapeutics Co.Ltd.
―
Delta-Fly Pharma, Inc.
―